Galapagos NV (GLPGA) | Financial Analysis & Statements
Galapagos NV Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
900.8M
Gross Profit
900.4M
99.95%
Operating Income
758.8M
84.23%
Net Income
782.1M
86.83%
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
170.6M
Shareholders Equity
3.2B
Debt to Equity
0.05
Cash Flow Metrics
Operating Cash Flow
-574.1M
Free Cash Flow
-49.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Galapagos NV Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 275.6M | 239.7M | 241.2M | 234.4M |
| Cost of Goods Sold | 29.7M | 34.9M | - | 12.1M | 1.6M |
| Gross Profit | 1.1B | 240.8M | - | 493.2M | 483.2M |
| Gross Margin % | 97.3% | 87.4% | 0.0% | 204.4% | 206.2% |
| Operating Expenses | |||||
| Research & Development | 459.4M | 335.5M | 241.3M | 269.8M | 320.5M |
| Selling, General & Administrative | 112.0M | 96.9M | 94.3M | 103.3M | 89.2M |
| Other Operating Expenses | 254.0K | -16.4M | -23.6M | -9.4M | -20.2M |
| Total Operating Expenses | 571.6M | 416.0M | 311.9M | 363.7M | 389.6M |
| Operating Income | 501.4M | -188.3M | -88.3M | -131.1M | -171.6M |
| Operating Margin % | 45.1% | -68.3% | -36.8% | -54.3% | -73.2% |
| Non-Operating Items | |||||
| Interest Income | 46.3M | 89.8M | 79.6M | 18.1M | 2.9M |
| Interest Expense | 2.2M | 911.0K | 1.8M | 9.2M | 11.6M |
| Other Non-Operating Income | -245.7M | 95.8M | 16.3M | 51.5M | 61.5M |
| Pre-tax Income | 300.9M | -3.1M | 5.6M | -70.8M | -119.4M |
| Income Tax | -18.6M | -1.8M | 9.6M | 572.0K | 1.4M |
| Effective Tax Rate % | -6.2% | 0.0% | 170.9% | 0.0% | 0.0% |
| Net Income | 320.9M | 74.1M | 211.7M | -218.0M | -103.2M |
| Net Margin % | 28.9% | 26.9% | 88.3% | -90.4% | -44.0% |
| Key Metrics | |||||
| EBITDA | 604.7M | -52.5M | 34.8M | -47.6M | -134.6M |
| EPS (Basic) | €4.87 | €1.12 | €3.21 | €-3.32 | €-1.58 |
| EPS (Diluted) | €4.87 | €1.12 | €3.21 | €-3.32 | €-1.58 |
| Basic Shares Outstanding | 65897000 | 66144643 | 65884000 | 65659940 | 65500000 |
| Diluted Shares Outstanding | 65897000 | 66144643 | 65884000 | 65659940 | 65500000 |
Income Statement Trend
Galapagos NV Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 87.9M | 64.2M | 166.8M | 508.1M | 2.2B |
| Short-term Investments | 2.9B | 3.1B | 3.5B | 3.6B | 2.5B |
| Accounts Receivable | 9.6M | 32.5M | 17.5M | 28.2M | 91.8M |
| Inventory | 22.5M | 51.2M | 74.0M | 52.9M | 20.6M |
| Other Current Assets | - | - | - | 2.0K | -1.0K |
| Total Current Assets | 3.1B | 3.3B | 3.9B | 4.2B | 4.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.2M | 8.6M | 6.8M | 11.6M | 60.3M |
| Goodwill | 848.0K | 304.9M | 267.0M | 286.0M | 60.1M |
| Intangible Assets | 848.0K | 164.9M | 127.9M | 146.4M | 60.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 177.6M | 179.9M | 148.2M | 127.1M | 133.7M |
| Total Non-Current Assets | 327.1M | 796.3M | 495.8M | 497.5M | 331.3M |
| Total Assets | 3.4B | 4.1B | 4.4B | 4.7B | 5.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 32.6M | 97.8M | 134.7M | 133.3M | 134.3M |
| Short-term Debt | 1.7M | 3.5M | 4.7M | 7.2M | 7.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 38.9M | 5.0K | 32.0M | 8.5M | 204.0K |
| Total Current Liabilities | 152.9M | 335.1M | 428.2M | 522.5M | 566.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.2M | 8.2M | 4.9M | 14.7M | 19.7M |
| Deferred Tax Liabilities | 0 | 20.7M | 23.6M | 20.1M | 0 |
| Other Non-Current Liabilities | 12.6M | 33.8M | 31.6M | 21.8M | 7.1M |
| Total Non-Current Liabilities | 17.8M | 903.7M | 1.1B | 1.7B | 2.0B |
| Total Liabilities | 170.6M | 1.2B | 1.6B | 2.2B | 2.5B |
| Equity | |||||
| Common Stock | 293.9M | 293.9M | 293.9M | 293.6M | 292.1M |
| Retained Earnings | 210.6M | -134.3M | -228.3M | -496.7M | -367.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.2B | 2.9B | 2.8B | 2.5B | 2.6B |
| Key Metrics | |||||
| Total Debt | 6.9M | 11.7M | 9.6M | 21.9M | 26.9M |
| Working Capital | 2.9B | 3.0B | 3.4B | 3.7B | 4.3B |
Balance Sheet Composition
Galapagos NV Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 320.9M | 74.1M | 211.7M | -218.0M | -103.2M |
| Depreciation & Amortization | 55.9M | 45.5M | 43.6M | 65.6M | 34.6M |
| Stock-Based Compensation | 24.0M | 19.9M | 56.7M | 88.5M | 70.7M |
| Working Capital Changes | -876.6M | -320.6M | -692.4M | -351.3M | -430.4M |
| Operating Cash Flow | -594.8M | -300.6M | -460.4M | -439.5M | -407.1M |
| Investing Activities | |||||
| Capital Expenditures | -13.2M | -16.7M | -16.3M | -26.6M | -54.2M |
| Acquisitions | 19.4M | -8.9M | -7.0M | -115.3M | 28.7M |
| Investment Purchases | -3.5B | -3.4B | -3.4B | -2.7B | -1.6B |
| Investment Sales | 3.7B | 3.7B | 3.5B | 1.6B | 2.1B |
| Investing Cash Flow | 228.5M | 256.5M | 57.0M | -1.2B | 544.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -3.3M | -4.9M | -6.8M | -8.2M | -7.2M |
| Financing Cash Flow | -3.3M | -4.9M | -5.0M | -1.5M | -3.9M |
| Free Cash Flow | -271.3M | -402.1M | -425.2M | -537.5M | -561.7M |
| Net Change in Cash | -369.5M | -49.0M | -408.4M | -1.7B | 133.9M |
Cash Flow Trend
Galapagos NV Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
5.10
Forward P/E
-6.32
Price to Book
0.50
Price to Sales
1.46
PEG Ratio
-6.32
Profitability Ratios
Profit Margin
28.85%
Operating Margin
88.00%
Return on Equity
10.42%
Return on Assets
8.87%
Financial Health
Current Ratio
20.14
Debt to Equity
0.21
Beta
0.15
Per Share Data
EPS (TTM)
€4.85
Book Value per Share
€49.11
Revenue per Share
€16.88
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GLPGA | 1.6B | 5.10 | 0.50 | 10.42% | 28.85% | 0.21 |
| Pharming Group N.V | 1.0B | 57.15 | 4.31 | 1.02% | 0.76% | 41.78 |
| Vivoryon | 37.0M | -1.58 | 11.07 | -145.47% | 0.00% | 2.26 |
| Koninklijke Philips | 22.2B | 25.04 | 2.02 | 7.82% | 5.02% | 73.57 |
| ASML Holding N.V | 481.6B | 48.06 | 22.96 | 52.24% | 29.71% | 12.99 |
| Shell plc | 212.6B | 14.90 | 1.47 | 10.19% | 6.68% | 43.17 |
Financial data is updated regularly. All figures are in the company's reporting currency.